66 related articles for article (PubMed ID: 21887474)
1. Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β-catenin signaling pathways.
Wang Y; Chen L; Bao Z; Li S; You G; Yan W; Shi Z; Liu Y; Yang P; Zhang W; Han L; Kang C; Jiang T
Oncol Rep; 2011 Nov; 26(5):1173-80. PubMed ID: 21887474
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities.
Das A; Banik NL; Patel SJ; Ray SK
Mol Cancer; 2004 Dec; 3(1):36. PubMed ID: 15588281
[TBL] [Abstract][Full Text] [Related]
3. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Narayan RS; Fedrigo CA; Brands E; Dik R; Stalpers LJ; Baumert BG; Slotman BJ; Westerman BA; Peters GJ; Sminia P
BMC Cancer; 2017 Mar; 17(1):204. PubMed ID: 28320338
[TBL] [Abstract][Full Text] [Related]
4. Identification of Key Candidate Proteins and Pathways Associated with Temozolomide Resistance in Glioblastoma Based on Subcellular Proteomics and Bioinformatical Analysis.
Yi GZ; Xiang W; Feng WY; Chen ZY; Li YM; Deng SZ; Guo ML; Zhao L; Sun XG; He MY; Qi ST; Liu YW
Biomed Res Int; 2018; 2018():5238760. PubMed ID: 29687002
[TBL] [Abstract][Full Text] [Related]
5. STAT3 phosphorylation inhibitor Bt354 exhibits anti-neoplastic activity in glioblastoma multiforme cells.
Chiang YC; Selvam P; Liu YX; Shih PC; Chen NF; Kuo HM; Lin HY; Wen ZH; Chen WF
Environ Toxicol; 2024 Jun; 39(6):3292-3303. PubMed ID: 38415901
[TBL] [Abstract][Full Text] [Related]
6. Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
Dvorakova K; Skarkova V; Vitovcova B; Soukup J; Vosmikova H; Pleskacova Z; Skarka A; Bartos MC; Krupa P; Kasparova P; Petera J; Rudolf E
BMC Cancer; 2024 Apr; 24(1):509. PubMed ID: 38654280
[TBL] [Abstract][Full Text] [Related]
7. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.
Kong LY; Wei J; Sharma AK; Barr J; Abou-Ghazal MK; Fokt I; Weinberg J; Rao G; Grimm E; Priebe W; Heimberger AB
Cancer Immunol Immunother; 2009 Jul; 58(7):1023-32. PubMed ID: 19002459
[TBL] [Abstract][Full Text] [Related]
8. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy.
Gregory JV; Kadiyala P; Doherty R; Cadena M; Habeel S; Ruoslahti E; Lowenstein PR; Castro MG; Lahann J
Nat Commun; 2020 Nov; 11(1):5687. PubMed ID: 33173024
[TBL] [Abstract][Full Text] [Related]
9. Prevention of STAT3-related pathway in SK-N-SH cells by natural product astaxanthin.
Sun SQ; Du FX; Zhang LH; Hao-Shi ; Gu FY; Deng YL; Ji YZ
BMC Complement Med Ther; 2023 Nov; 23(1):430. PubMed ID: 38031104
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation.
Wu M; Song D; Li H; Ahmad N; Xu H; Yang X; Wang Q; Cheng X; Deng S; Shu X
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298405
[TBL] [Abstract][Full Text] [Related]
11. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.
Groot J; Ott M; Wei J; Kassab C; Fang D; Najem H; O'Brien B; Weathers SP; Matsouka CK; Majd NK; Harrison RA; Fuller GN; Huse JT; Long JP; Sawaya R; Rao G; MacDonald TJ; Priebe W; DeCuypere M; Heimberger AB
CNS Oncol; 2022 Jun; 11(2):CNS87. PubMed ID: 35575067
[No Abstract] [Full Text] [Related]
12. An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.
Xiao G; Gao X; Li L; Liu C; Liu Z; Peng H; Xia X; Yi X; Zhou R
J Oncol; 2021; 2021():3766685. PubMed ID: 34961815
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review.
Singh N; Miner A; Hennis L; Mittal S
Cancer Drug Resist; 2021; 4(1):17-43. PubMed ID: 34337348
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box protein O3a promotes glioma cell resistance to temozolomide by regulating matrix metallopeptidase and β-catenin.
Sun D; Yang S; Zhang X; Li S; Wang L; Chen J; Qiu C; Xu K
Oncol Lett; 2021 Apr; 21(4):328. PubMed ID: 33692860
[TBL] [Abstract][Full Text] [Related]
15. The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma.
Ou A; Ott M; Fang D; Heimberger AB
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498872
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and Prognostic Roles of STAT3 and Its Phosphorylation in Glioma.
Liang B; Li SY; Gong HZ; Wang LX; Lu J; Zhao YX; Gu N
Dis Markers; 2020; 2020():8833885. PubMed ID: 33299498
[TBL] [Abstract][Full Text] [Related]
17. Signaling pathways and mesenchymal transition in pediatric high-grade glioma.
Meel MH; Schaper SA; Kaspers GJL; Hulleman E
Cell Mol Life Sci; 2018 Mar; 75(5):871-887. PubMed ID: 29164272
[TBL] [Abstract][Full Text] [Related]
18. EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.
Yu Q; Liu L; Wang P; Yao Y; Xue Y; Liu Y
Cell Cycle; 2017 Jun; 16(11):1085-1092. PubMed ID: 28436750
[TBL] [Abstract][Full Text] [Related]
19. Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
Velpula KK; Guda MR; Sahu K; Tuszynski J; Asuthkar S; Bach SE; Lathia JD; Tsung AJ
Oncotarget; 2017 May; 8(22):35639-35655. PubMed ID: 28410193
[TBL] [Abstract][Full Text] [Related]
20. Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.
Ouédraogo ZG; Biau J; Kemeny JL; Morel L; Verrelle P; Chautard E
Mol Neurobiol; 2017 Oct; 54(8):5780-5797. PubMed ID: 27660268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
